A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/mL at initial biopsy.
Biomarkers, Tumor
Biopsy
Cell-Free Nucleic Acids
Extracellular Vesicles
/ metabolism
Gene Expression Profiling
High-Throughput Nucleotide Sequencing
Humans
Male
Neoplasm Grading
Prognosis
Prostate-Specific Antigen
/ urine
Prostatic Neoplasms
/ diagnosis
RNA, Circular
/ genetics
ROC Curve
Reproducibility of Results
Circular RNA (circRNA)
Diagnosis
Extracellular vesicle
Prostate cancer
Urine
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
23 07 2021
23 07 2021
Historique:
received:
07
01
2021
accepted:
25
06
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
27
1
2022
Statut:
epublish
Résumé
The aim of this study was to identify a urine extracellular vesicle circular RNA (circRNA) classifier that could detect high-grade prostate cancer (PCa) of Grade Group (GG) 2 or greater. For this purpose, we used RNA sequencing to identify candidate circRNAs from urinary extracellular vesicles from 11 patients with high-grade PCa and 11 case-matched patients with benign prostatic hyperplasia. Using ddPCR in a training cohort (n = 263), we built a urine extracellular vesicle circRNA classifier (Ccirc, containing circPDLIM5, circSCAF8, circPLXDC2, circSCAMP1, and circCCNT2), which was evaluated in two independent cohorts (n = 497, n = 505). Ccirc showed higher accuracy than two standard of care risk calculators (RCs) (PCPT-RC 2.0 and ERSPC-RC) in both the training cohort and the validation cohorts. In all three cohorts, this novel urine extracellular vesicle circRNA classifier plus RCs was statistically more predictive than RCs alone for predicting ≥ GG2 PCa. This assay, which does not require precollection digital rectal examination nor special handling, is repeatable, noninvasive, and can be easily implemented as part of the basic clinical workflow.
Identifiants
pubmed: 34301266
doi: 10.1186/s12943-021-01388-6
pii: 10.1186/s12943-021-01388-6
pmc: PMC8299620
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
RNA, Circular
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
96Informations de copyright
© 2021. The Author(s).
Références
Urology. 2014 Jun;83(6):1362-7
pubmed: 24862395
Cell. 2019 Feb 7;176(4):831-843.e22
pubmed: 30735634
Lancet Oncol. 2012 Nov;13(11):e509-17
pubmed: 23117005
Mol Cancer. 2019 Jul 5;18(1):116
pubmed: 31277663
Eur Urol. 2005 Sep;48(3):386-99; discussion 398-9
pubmed: 15982797
BJU Int. 2016 Nov;118(5):706-713
pubmed: 26833820
Cell. 2019 Feb 7;176(4):869-881.e13
pubmed: 30735636
Eur Urol. 2016 Jul;70(1):45-53
pubmed: 25985884
Mol Cancer. 2018 Jul 23;17(1):103
pubmed: 30037351
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
Am J Surg Pathol. 2017 Apr;41(4):e1-e7
pubmed: 28177964
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593